Creative Medical Technology Holdings, Inc.
CELZHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeCreative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and. With a market capitalization of $5.4M, it sits in micro-cap territory. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Market Cap
$5.4M
Beta
1.88
P/E (TTM)
—
P/E (Fwd)
-0.97
EPS (TTM)
$-2.01
EPS (Fwd)
$-0.86
ROE
-81.2%
ROA
-50.2%
Cash
$5.8M
Total Debt
$14,194
Free CF
-$3.6M
52W Change
-69.7%
Annual Financials
Cash vs Debt
Where CELZ stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CELZ finished 58.00% below its 150-day moving average ($2.00) and 63.79% below its 200-day moving average ($2.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CELZ overbought or oversold?
At the July 15, 2026 close, CELZ's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.8M in cash and $14K in debt, CELZ maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$3.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -81.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $89K (2022) to $6K (2025), a 93% decline worth watching.
With a beta above 1.5, CELZ tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CELZ's risk profile alongside its fundamentals and technical indicators provides a more complete picture.